NCT04941196View on ClinicalTrials.gov

Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

October 26, 2020

Study Completion Date

November 25, 2020

Conditions
Healthy Individuals
Interventions
DRUG

Anplag (Ticagrelor 90 mg)

Ticagrelor 90 mg Immediate Release tablet

DRUG

Brilinta (Ticagrelor 90 mg)

Ticagrelor 90 mg Immediate Release tablet

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research, Karachi

All Listed Sponsors
collaborator

PharmEvo Private Limited., Pakistan

UNKNOWN

lead

University of Karachi

OTHER

NCT04941196 - Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition | Biotech Hunter | Biotech Hunter